

Attorney Docket No.: 4401.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dyrberg et al.

Serial No.: 09/847,623

Group Art Unit: 1639

RECEIVED
CENTRAL FAX CENTER

Filed: May 2, 2001

Examiner: B. Celsa

OCT 25 2004

Confirmation No: 6709

For: Treatment of Type I Diabetes

CERTIFICATE OF FACSIMILE TRANSMISSION
703-872-9306Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Petition and Fee for Extension of Time
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner B. Celsa Confirmation No: 6709, fax number (703) 872-9306.

Respectfully submitted,

Date: October 25, 2004

Csaba Attila Szakolcza
Csaba Attila Szakolcza
Novo Nordisk® Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Attorney Docket No.: 4401.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dyrberg et al.

Application No.: 09/847,623

Group Art Unit: 1639

Filed: May 2, 2001

Examiner: B. Celsa

For: Treatment of Type I Diabetes

RESPONSE UNDER 37 C.F.R. § 1.116

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed April 28, 2004, in the above-identified application, kindly consider the following remarks.

Listing of Claims are set forth starting at Page 2 of this paper.

Remarks concerning these amendments are set forth beginning at Page 3 of this paper.